New York, September 24, 2024 - PRISM MarketView - Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on cell and exosome-based therapies, has announced its intent to file a Biologics License Application (BLA) for deramiocel (CAP-1002) for the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. The BLA submission is expected to begin in October 2024 and will be supported by positive cardiac data from Phase 2 HOPE-2 trials and natural history data. Full submission is anticipated by the end of 2024. Following the announcement, Capricor’s stock surged, closing up 52.43%.
Key Highlights:
- Label Expansion Potential: The initial approval would target cardiomyopathy in DMD patients, with potential for label expansion to include skeletal muscle myopathy pending positive results from the ongoing Phase 3 HOPE-3 trial.
- Significant Market Opportunity: The DMD drugs market is projected to reach $5.5 billion by 2032. Approximately 25-59% of DMD patients develop cardiomyopathy, positioning deramiocel to meet a significant unmet need.
- Regulatory Path: Deramiocel has FDA Orphan Drug Designation and RMAT designation. If approved, Capricor would be eligible for a Priority Review Voucher, potentially worth over $100 million.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities